We describe zanubrutinib as a potential inhibitor of the HER2 signalling pathway, displaying antiproliferative effects in HER2-positive breast cancer cell lines, and we propose zanubrutinib as a candidate drug to be further investigated as a therapeutic agent in HER2-amplified breast cancer. Here, ERBB2 is linked to breast carcinoma.